TNF Receptor and TNF Antibodies
TNF receptor-targeted therapies are at the forefront of treatments for oncology and autoimmune diseases, including arthritis and inflammatory bowel disease (IBD). Modulating TNF receptors is crucial in these treatments, using the dual approach of antagonistic and agonistic antibodies to fine-tune immune responses. No matter which disease you delve into, the antibodies you choose serve as your most crucial tool. They help you achieve clearer insights and more conclusive results.
Agonistic and Antagonistic
Hycult Biotech has made a precise selection of antibodies that target TNF receptors and TNF-alpha. These antibodies play a dual role as essential biomarkers and functional active reagents, providing crucial insights into the complex inflammatory cascade of the TNF signalling pathway. Antagonistic antibodies to TNF receptors play a key role in reducing inflammation and autoimmune responses. On the flip side, agonistic antibodies enhance the efficacy of TNF receptors. As an example, the widely used MR2-1 antibody has shown to be a valuable tool for modulation of regulatory T Cell (Treg) activity. Find the right antibody for your research in the selection below:
| Antibody Name | Applications | Characteristics/notes | Article Number |
|---|---|---|---|
| TNF-RI | |||
| TNF-RI, Mouse, mAb HM104 | FC, F, IA, IP | HM1009 | |
| TNF-RI, Mouse, mAb 55R-170 | FC, FS | Antagnostic antibody useful for blocking of TNR-RI both in vitro and in vivo | HM1097 |
| TNF-RI, Mouse, pAb | FC, FS, IA, IP, WB | HP8002 | |
| TNF-RI, Human, mAb MR1-2 | FC, FS | HM2005 | |
| TNF-RI, Human, mAb H398 | FC, F, FS, IA, IP, WB | HM2020 | |
| TNF-RII | |||
| TNF-RII, Mouse, mAb HM102 | FC, FS | Agonistic | HM1011 |
| TNF-RII, Human, mAb MR2-1 | FC, FS | Agonistic antibody and receptor modulating antibody, useful for cell (culture) experiments | HM2007 |
| TNF-RII, Human, mAb 80M2 | FC, FS | Functions as an allosteric modulator, which stabilizes the ligand-receptor complex | HM2022 |
| TNF-RII, Mouse, pAb | FC, FS, IA, IP, WB | HP8003 | |
| TNF-RII, Human, pAb | FC, FS, IA, IP, WB | HP9003 | |
| TNF-alpha | |||
| TNF-alpha, Mouse, mAb V1q | FC, FS | Neutralizing antibody | HM1021 |
| TNF-alpha, Human, mAb 4H31 | FC, FS, F, IA, IP, WB | Useful for inhibition of the biological activity of TNF-alpha | HM2009 |
| TNF-alpha, Human, mAb 52B83 | FC, F, IA, WB | HM2010 | |
| TNF-alpha, Human, mAb T1 | FC, FS, IA, WB | Useful for inhibition of the biological activity of TNF-alpha | HM2024 |
| TNF-alpha, Human, mAb T3 | FC, FS, IA, IP, WB | Useful for inhibition of the biological activity of TNF-alpha | HM2026 |
| TNF-alpha, Human, mAb 5N | FS, IA | Useful for inhibition of the biological activity of TNF-alpha | HM2218 |
| TNF-alpha, Mouse, pAb | FC, F, FS, IA, P, WB | HP8001 | |
| TNF-alpha, Human, pAb | FC, FS, IA, WB | HP9001 |
Our services
We understand the value of good antibody production. Antibodies are key in company processes and even commercial operations. The production of your antibodies should therefore be something which you should not have to worry about. Use our knowledge to develop your next product. Find out more about the services of our sister company Biocult and get customized support tailored to your needs.
Latest Hycult Biotech news
- A New Chapter for Hycult Biotech
As of October 1st, 2025, we’re pleased to announce a change in our management structure at Hycult Biotech. Our Managing Director, Ronald de Niet, is stepping back from daily operations to focus on strategy and long-term development as CEO. Marja van Genugten has been appointed COO, taking responsibility for day-to-day management and internal operations to… Read more: A New Chapter for Hycult Biotech - New C3bBbP ELISA
We are happy to introduce our new ELISA kit developed to determine in vitro quantitative C3bBbP levels in serum and plasma samples. The C3 convertase, C3bBbP arises during Alternative Pathway (AP) activation and is an essential factor for proper functioning of the complement system as first line defense against pathogens. C3bBbP can lead to rare kidney… Read more: New C3bBbP ELISA - The Key to MAC Detection: Order the Specific Antibody for MAC
New Antibody for Detection of the Membrane Attack Complex The three distinct complement activation pathways converge at the formation of C3 convertase. This leads to the generation of C3b which triggers the assembly of the C5 convertase. This cleavage of C5 initiates the lytic, or terminal, pathway. Unlike the activation pathways that depend on enzymatic… Read more: The Key to MAC Detection: Order the Specific Antibody for MAC
